magnolol has been researched along with Acute Confusional Senile Dementia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, X; Fang, Y; Jia, R; Kang, X; Zhao, R; Zhu, G | 1 |
| Chen, T; Guo, X; Shou, L; Tao, T; Wei, M; Zheng, H | 1 |
| Jia, J; Wang, X | 1 |
| Fu, Y; Hölscher, C; Jiang, Y; Wang, H; Xie, Z; Xu, J; Yang, Q; Zeng, H; Zhang, Z; Zhao, J | 1 |
| Akae, H; Akagi, M; Akagi, R; Fukuishi, N; Fukuyama, Y; Hirashima, N; Matsui, N | 1 |
| Baum, L; Chow, AH; Ho, YP; Hoi, CP | 1 |
1 review(s) available for magnolol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Nonpeptide neurotrophic agents useful in the treatment of neurodegenerative diseases such as Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Biphenyl Compounds; Cells, Cultured; Dietary Supplements; Hippocampus; Humans; Lignans; Magnolia; Mice; Molecular Weight; Nerve Growth Factors; Neurodegenerative Diseases; Neurogenesis; Phytotherapy; Polyphenols; Rats; Structure-Activity Relationship; Zingiberales | 2015 |
5 other study(ies) available for magnolol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Magnolol upregulates CHRM1 to attenuate Amyloid-β-triggered neuronal injury through regulating the cAMP/PKA/CREB pathway.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Apoptosis; Biphenyl Compounds; Humans; Lignans; Neurodegenerative Diseases; Neurons; Receptor, Muscarinic M1 | 2022 |
Magnolol attenuates the locomotor impairment, cognitive deficit, and neuroinflammation in Alzheimer's disease mice with brain insulin resistance via up-regulating miR-200c.
Topics: Alzheimer Disease; Animals; Antagomirs; Biphenyl Compounds; Brain; Disease Models, Animal; Insulin Resistance; Lignans; Locomotion; Male; Malondialdehyde; Mice; Morris Water Maze Test; Spatial Learning; Streptozocin | 2022 |
Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Animals; Autophagy; Cognitive Dysfunction; Mammals; Mice; Mice, Transgenic; Neurodegenerative Diseases; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases | 2023 |
Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Apolipoproteins E; Biphenyl Compounds; Caenorhabditis elegans; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Inflammation; Lignans; Microglia; NF-kappa B; Phagocytosis; PPAR gamma | 2020 |
Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Biphenyl Compounds; Calcium; Caspase 3; Cell Survival; Drugs, Chinese Herbal; Lignans; Magnolia; Neuroprotective Agents; PC12 Cells; Rats; Reactive Oxygen Species | 2010 |